Kevin Richard Haas - 13 Mar 2026 Form 4 Insider Report for MYRIAD GENETICS INC (MYGN)

Role
Chief Technology Officer
Signature
By: Justin Hunter For: Kevin Richard Haas
Issuer symbol
MYGN
Transactions as of
13 Mar 2026
Net transactions value
$0
Form type
4
Filing time
16 Mar 2026, 17:58:00 UTC
Previous filing
03 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Haas Kevin Richard Chief Technology Officer 322 NORTH 2200 WEST, SALT LAKE CITY By: Justin Hunter For: Kevin Richard Haas 16 Mar 2026 0001843872

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MYGN Common Stock Tax liability -6,412 -3.2% $4.66* 195,920 13 Mar 2026 Direct F1
transaction MYGN Common Stock Tax liability -4,161 -2.1% $4.66* 191,759 14 Mar 2026 Direct F1
transaction MYGN Common Stock Tax liability -3,355 -1.7% $4.66* 188,404 15 Mar 2026 Direct F1
transaction MYGN Common Stock Tax liability -8,382 -4.4% $4.66* 180,022 15 Mar 2026 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Kevin Richard Haas is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on March 13, 2026.
F2 Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of the Issuer's Common Stock on March 13, 2026.

Remarks:

The Reporting Person is no longer serving in the role of Chief Technology Officer of Myriad Genetics, Inc., effective March 16, 2026, and therefore is no longer subject to Section 16 reporting.